Literature DB >> 33535425

Adipokines and Metabolic Regulators in Human and Experimental Pulmonary Arterial Hypertension.

Aimilia Eirini Papathanasiou1,2,3, Fotios Spyropoulos1,2, Zoe Michael2,4, Kyoung E Joung1,2, Despina D Briana3, Ariadne Malamitsi-Puchner3, Christos S Mantzoros2,5,6, Helen Christou1,2.   

Abstract

Pulmonary hypertension (PH) is associated with meta-inflammation related to obesity but the role of adipose tissue in PH pathogenesis is unknown. We hypothesized that adipose tissue-derived metabolic regulators are altered in human and experimental PH. We measured circulating levels of fatty acid binding protein 4 (FABP-4), fibroblast growth factor -21 (FGF-21), adiponectin, and the mRNA levels of FABP-4, FGF-21, and peroxisome proliferator-activated receptor γ (PPARγ) in lung tissue of patients with idiopathic PH and healthy controls. We also evaluated lung and adipose tissue expression of these mediators in the three most commonly used experimental rodent models of pulmonary hypertension. Circulating levels of FABP-4, FGF-21, and adiponectin were significantly elevated in PH patients compared to controls and the mRNA levels of these regulators and PPARγ were also significantly increased in human PH lungs and in the lungs of rats with experimental PH compared to controls. These findings were coupled with increased levels of adipose tissue mRNA of genes related to glucose uptake, glycolysis, tricarboxylic acid cycle, and fatty acid oxidation in experimental PH. Our results support that metabolic alterations in human PH are recapitulated in rodent models of the disease and suggest that adipose tissue may contribute to PH pathogenesis.

Entities:  

Keywords:  adipose tissue; meta-inflammation; pulmonary hypertension

Mesh:

Substances:

Year:  2021        PMID: 33535425      PMCID: PMC7867052          DOI: 10.3390/ijms22031435

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  70 in total

1.  Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease.

Authors:  Benoît Ranchoux; Valérie Nadeau; Alice Bourgeois; Steeve Provencher; Éve Tremblay; Junichi Omura; Nancy Coté; Rami Abu-Alhayja'a; Valérie Dumais; Renato T Nachbar; Lionel Tastet; Abdellaziz Dahou; Sandra Breuils-Bonnet; André Marette; Philippe Pibarot; Jocelyn Dupuis; Roxane Paulin; Olivier Boucherat; Stephen L Archer; Sébastien Bonnet; François Potus
Journal:  Circ Res       Date:  2019-06-03       Impact factor: 17.367

2.  Mutual promotion of FGF21 and PPARγ attenuates hypoxia-induced pulmonary hypertension.

Authors:  Gexiang Cai; Jingjing Liu; Meibin Wang; Lihuang Su; Mengsi Cai; Kate Huang; Xiuchun Li; Manxiang Li; Liangxing Wang; Xiaoying Huang
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

3.  Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats.

Authors:  Eun Kyung Kim; Ji-Hyun Lee; Yeon-Mock Oh; Yun-Song Lee; Sang-Do Lee
Journal:  Respirology       Date:  2010-05       Impact factor: 6.424

4.  Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth.

Authors:  Shingo Ameshima; Heiko Golpon; Carlyne D Cool; Daniel Chan; R William Vandivier; Shyra J Gardai; Marilee Wick; Raphael A Nemenoff; Mark W Geraci; Norbert F Voelkel
Journal:  Circ Res       Date:  2003-04-24       Impact factor: 17.367

Review 5.  Metabolic Dysfunction in Pulmonary Arterial Hypertension.

Authors:  Tufik R Assad; Anna R Hemnes
Journal:  Curr Hypertens Rep       Date:  2015-03       Impact factor: 5.369

Review 6.  The Randle cycle revisited: a new head for an old hat.

Authors:  Louis Hue; Heinrich Taegtmeyer
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-16       Impact factor: 4.310

Review 7.  The FGF21-adiponectin axis in controlling energy and vascular homeostasis.

Authors:  Xiaoyan Hui; Tianshi Feng; Qing Liu; Yuan Gao; Aimin Xu
Journal:  J Mol Cell Biol       Date:  2016-03-18       Impact factor: 6.216

8.  Activation of the retinoid X receptor modulates angiotensin II-induced smooth muscle gene expression and inflammation in vascular smooth muscle cells.

Authors:  Allison M B Lehman; John R Montford; Henrick Horita; Allison C Ostriker; Mary C M Weiser-Evans; Raphael A Nemenoff; Seth B Furgeson
Journal:  Mol Pharmacol       Date:  2014-08-28       Impact factor: 4.436

9.  A2A Receptor Activation Attenuates Hypertensive Cardiac Remodeling via Promoting Brown Adipose Tissue-Derived FGF21.

Authors:  Cheng-Chao Ruan; Ling-Ran Kong; Xiao-Hui Chen; Yu Ma; Xiao-Xi Pan; Ze-Bei Zhang; Ping-Jin Gao
Journal:  Cell Metab       Date:  2018-07-12       Impact factor: 27.287

10.  PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation.

Authors:  Ekaterina Legchenko; Philippe Chouvarine; Paul Borchert; Angeles Fernandez-Gonzalez; Erin Snay; Martin Meier; Lavinia Maegel; S Alex Mitsialis; Eva A Rog-Zielinska; Stella Kourembanas; Danny Jonigk; Georg Hansmann
Journal:  Sci Transl Med       Date:  2018-04-25       Impact factor: 17.956

View more
  3 in total

Review 1.  Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases.

Authors:  Min-Qi Jia; Cha-Xiang Guan; Jia-Hao Tao; Yong Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-05-29       Impact factor: 7.310

Review 2.  Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.

Authors:  Alana Aragón-Herrera; Sandra Feijóo-Bandín; Laura Anido-Varela; Sandra Moraña-Fernández; Esther Roselló-Lletí; Manuel Portolés; Estefanía Tarazón; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago
Journal:  J Pers Med       Date:  2022-06-21

3.  BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.

Authors:  Breanne E McCarthy; Robyn L McClelland; Dina H Appleby; Jude S Moutchia; Jasleen K Minhas; Jeff Min; Jeremy A Mazurek; K Akaya Smith; Jason S Fritz; Steven C Pugliese; Ryan J Urbanowicz; John H Holmes; Harold I Palevsky; Steven M Kawut; Nadine Al-Naamani
Journal:  Chest       Date:  2022-03-03       Impact factor: 10.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.